Mesoblast Ltd financial data

Symbol
MESO on Nasdaq, MEOBF on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
Level 38, 55 Collins Street, Melbourne, Victoria, Australia
State of incorporation
Australia
Fiscal year end
June 30
Latest financial report
20-F - Q2 2023 - Aug 31, 2023

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 814M shares +25.2%

Income Statement

Label TTM Value / Value Unit Change %
Research And Development Expense 27.2M USD -17.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets 670M USD +0.33%
Liabilities 162M USD -3.87%

Popular Metrics

Label TTM Value / Value Unit Change %
Interest Expense 19.4M USD +15%